ADHD Therapeutics Market Size, Share, Growth by 2030

The global market for ADHD therapeutics is projected to grow significantly, reaching approximately US$ 64,742.37 billion by 2030, up from US$ 28,594.55 billion in 2022. This growth represents a compound annual growth rate (CAGR) of 10.8% from 2022 to 2030.

Several key factors are contributing to the expansion of the ADHD therapeutics market, including the rising incidence of ADHD, heightened awareness among patients and their families, and an increasing focus on research and development in the field of ADHD treatments. However, challenges such as the side effects associated with ADHD medications and their often limited effectiveness in alleviating symptoms may impede market growth.

Market Drivers for ADHD Therapeutics

The prevalence of ADHD and the growing focus on research and development in ADHD therapeutics are significant drivers of market growth.

According to a report from the Centers for Disease Control and Prevention (CDC) published in February 2022, around 6 million children aged 3 to 17 in the United States were diagnosed with ADHD, representing 9.8% of the population from 2016 to 2019. Furthermore, a study published in PubMed Central in 2022 indicated that ADHD affects between 5% to 7.2% of children and 2.5% to 6.7% of adults globally. Recent estimates suggest that the prevalence among adolescents in the U.S. is even higher, at approximately 8.7%, or about 5.3 million individuals. While ADHD has traditionally been viewed as a childhood disorder, it is important to note that up to 90% of children diagnosed with ADHD continue to experience symptoms into adulthood. Research indicates that 75% of adults with ADHD were not diagnosed during their childhood, highlighting the need for adult diagnosis and treatment. ADHD is often accompanied by comorbid conditions such as anxiety, depression, learning disabilities, and substance abuse, which complicate treatment and necessitate a comprehensive approach that addresses both ADHD symptoms and these associated conditions. Medications, including psychostimulants and non-stimulants, are commonly prescribed to help children manage their ADHD symptoms, thereby improving their daily functioning and academic performance. Consequently, the increasing prevalence of ADHD, coupled with the rising demand for effective treatment options, is driving market growth.

Additionally, the ADHD therapeutics market is poised for growth due to ongoing advancements in medical treatments, an increase in neuroscience research initiatives, and a growing public awareness of mental health issues. Increased understanding among patients, caregivers, and healthcare professionals regarding the impact of ADHD on daily life has led to a greater willingness to pursue effective therapeutic options. The rising number of individuals affected by various mental health disorders, including ADHD, has prompted governments worldwide to take action. Pharmaceutical and biotechnology companies are also focusing on developing innovative ADHD treatments. For instance, in July 2021, the New South Wales (NSW) government in Australia allocated US$ 1.8 million to an ADHD pilot program for 2021-2022, with a total investment of US$ 7.7 million over four years aimed at trialing a new care model for children with behavioral issues, including ADHD.

Opportunities in the ADHD Therapeutics Market

The ongoing development of new pharmacological treatments, particularly non-stimulants, offers significant opportunities for addressing ADHD, managing emerging side effects, and broadening the range of available treatment options. Furthermore, collaborative efforts among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for identifying new therapeutic targets, fostering innovation, expediting clinical trials, and enhancing access to ADHD therapeutics and support services.

ADHD Therapeutics Market: Segmental Overview

The ADHD therapeutics market is categorized by drug type into stimulant and non-stimulant medications. The stimulant drugs segment held a larger share of the market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030.

By age group, the market is divided into pediatric & adolescent and adult segments. The pediatric & adolescent segment accounted for the largest market share in 2022, while the adult segment is projected to experience the highest CAGR during the forecast period from 2022 to 2030.

In terms of distribution channels, the ADHD therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2030.

ADHD Therapeutics Market: Geographical Overview

The Asia Pacific region is emerging as the fastest-growing market for ADHD therapeutics, driven by key regional players and various strategic initiatives aimed at developing and marketing new products. For example, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced positive outcomes from two six-week phase 3 clinical trials evaluating the efficacy, safety, and tolerability of oral centanafadine, a new experimental drug for adults with ADHD. The company also plans to investigate the effects of centanafadine in children with ADHD and engage with the U.S. Food and Drug Administration regarding future steps.

In 2022, North America held the largest share of the global ADHD therapeutics market, with the U.S. leading the market. The high prevalence of ADHD in the U.S. is a significant factor driving market growth. According to Cingulate, approximately 6.4 million children and adolescents aged 4 to 17 were diagnosed with ADHD in 2022, with over 80% receiving treatment and around 65% continuing to experience symptoms into adulthood. Additionally, factors such as improved patient affordability, favorable reimbursement policies, and increased awareness of available treatments are expected to further propel market growth.